Every GLP-1 brand, and what each one is licensed for

The full set

Five molecules carry nine brand names between them. The split that matters is not brand against brand but indication against indication: some are licensed for weight management, some only for type 2 diabetes, and the manufacturers of the diabetes brands say so unusually bluntly.

Only four are licensed for weight

• ◆Wegovy (semaglutide) — injection and tablet.
• ◆Zepbound (tirzepatide) — injection, and separately indicated for obstructive sleep apnoea in adults with obesity.
• ◆Foundayo (orforglipron) — the first oral small-molecule GLP-1, and the only one of the four with no diabetes sibling brand.
• ◆Saxenda (liraglutide) — the only one with a paediatric weight indication, for children aged 12–17 above 132 lbs, and the only one being withdrawn.

The label differs by country

There is now a generic — but only in the UK

Nevolat is a generic liraglutide, the first generic GLP-1 to reach a consumer market. PrivateDoc describes it directly as “generic Saxenda.” It is sold across the British pharmacies in this research — Boots at £140.40 for three pens, PrivateDoc from £64.99 for one, Medino, Prescription Doctor from £64.99, MyPharmacy from £119.

The comparison that matters appears on a single page: MyPharmacy lists branded Saxenda from £399 and Nevolat, the same molecule, from £119. Novo Nordisk is discontinuing the branded product. There is no generic semaglutide or tirzepatide anywhere in either market — liraglutide is first because it is oldest.

The brands that have already gone

This class is consolidating fast, and the older agents are being cleared out as the newer ones take over. Three brands have already been withdrawn from the US market and a fourth is on its way out.

The practical read: if a service offers you one of the older agents, ask about supply before you build a plan around it. Exenatide and lixisenatide are gone; liraglutide’s weight-management brand is going.

What is coming next

One combination has published phase 3 results and is worth knowing about before committing to a long prepaid plan on something else. CagriSema is a once-weekly combination of semaglutide and cagrilintide — the latter an amylin analogue rather than a GLP-1.

Several other agents are in trials — retatrutide, survodutide and mazdutide among them, working on glucagon and GIP receptors alongside GLP-1. We are not quoting effect sizes for those: the primary trial publications were not retrievable during this research, and secondhand figures for unapproved drugs are exactly the kind of number that should not be repeated without a source.

Route, not just molecule

Two of the nine are tablets rather than injections, and they are not equivalent to each other. Rybelsus is oral semaglutide — a peptide, which is why it carries a strict administration routine: take it “on an empty stomach in the morning with water (no more than 4 ounces),” then wait 30 minutes before eating, drinking or taking other oral medicines.

Foundayo is orforglipron, a small molecule rather than a peptide, and carries no comparable timing requirement — Lilly says only to swallow tablets whole without breaking, crushing or chewing them. If the injection is the obstacle, those are two very different daily routines.

What this changes when you shop

• ◆Ask for the brand that matches your indication. For weight, that is Wegovy, Zepbound or Foundayo — and on verified prices those are also the cheaper routes, because the manufacturer self-pay programmes are attached to them.
• ◆A quote for Mounjaro or Ozempic at $1,000–$1,900 a month is a retail cash price with no programme applied. The weight-management sibling is usually a fraction of it.
• ◆If a service is selling you Saxenda, ask about supply before you start.
• ◆If you want a tablet, establish which tablet. Rybelsus and Foundayo are different molecules with different indications and very different daily routines.